Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eur Urol Oncol. 2021 Aug;4(4):532-539. doi: 10.1016/j.euo.2021.03.006. Epub 2021 Apr 15.
Pelvic lymph node dissection (PLND) is the most reliable procedure for lymph node staging. However, the therapeutic benefit remains unproven; although most radical prostatectomies at academic centers are accompanied by PLND, there is no consensus regarding the optimal anatomical extent of PLND.
To evaluate whether extended PLND results in a lower biochemical recurrence rate.
DESIGN, SETTING, AND PARTICIPANTS: We conducted a single-center randomized trial. Patients, enrolled between October 2011 and March 2017, were scheduled to undergo radical prostatectomy and PLND. Patients were assigned to limited or extended PLND by cluster randomization. Specifically, surgeons were randomized to perform limited or extended PLND for 3-mo periods.
Randomization to limited (external iliac nodes) or extended (external iliac, obturator fossa and hypogastric nodes) PLND.
The primary endpoint was the rate of biochemical recurrence.
Of 1440 patients included in the final analysis, 700 were randomized to limited PLND and 740 to extended PLND. The median number of nodes retrieved was 12 (interquartile range [IQR] 8-17) for limited PLND and 14 (IQR 10-20) extended PLND; the corresponding rate of positive nodes was 12% and 14% (difference -1.9%, 95% confidence interval [CI] -5.4% to 1.5%; p = 0.3). With median follow-up of 3.1 yr, there was no significant difference in the rate of biochemical recurrence between the groups (hazard ratio 1.04, 95% CI 0.93-1.15; p = 0.5). Rates for grade 2 and 3 complications were similar at 7.3% for limited versus 6.4% for extended PLND; there were no grade 4 or 5 complications.
Extended PLND did not improve freedom from biochemical recurrence over limited PLND for men with clinically localized prostate cancer. However, there were smaller than expected differences in nodal count and the rate of positive nodes between the two templates. A randomized trial comparing PLND to no node dissection is warranted.
In this clinical trial we did not find a difference in the rate of biochemical recurrence of prostate cancer between limited and extended dissection of lymph nodes in the pelvis. This study is registered on ClinicalTrials.gov as NCT01407263.
盆腔淋巴结清扫术(PLND)是淋巴结分期最可靠的方法。然而,其治疗益处尚未得到证实;尽管大多数学术中心的根治性前列腺切除术都伴有 PLND,但对于 PLND 的最佳解剖范围尚未达成共识。
评估广泛的 PLND 是否会降低生化复发率。
设计、地点和参与者:我们进行了一项单中心随机试验。2011 年 10 月至 2017 年 3 月期间,患者被安排接受根治性前列腺切除术和 PLND。患者通过聚类随机分配接受局限性或广泛性 PLND。具体来说,外科医生被随机分配进行为期 3 个月的局限性或广泛性 PLND。
随机分为局限性(髂外淋巴结)或广泛性(髂外、闭孔窝和腹下淋巴结)PLND。
主要终点是生化复发率。
在最终分析的 1440 名患者中,700 名被随机分配至局限性 PLND,740 名被随机分配至广泛性 PLND。局限性 PLND 中中位数为 12 个(四分位距 [IQR] 8-17),广泛性 PLND 为 14 个(IQR 10-20);相应的阳性淋巴结率为 12%和 14%(差异-1.9%,95%置信区间 [CI] -5.4%至 1.5%;p=0.3)。中位随访 3.1 年后,两组间生化复发率无显著差异(风险比 1.04,95%CI 0.93-1.15;p=0.5)。局限性 PLND 的 2 级和 3 级并发症发生率为 7.3%,广泛性 PLND 为 6.4%;无 4 级或 5 级并发症。
对于患有临床局限性前列腺癌的男性,广泛的 PLND 并不能改善生化无复发生存率,而不是局限性 PLND。然而,在两种模板之间,淋巴结计数和阳性淋巴结的比例差异较小。有必要进行比较 PLND 与无淋巴结清扫术的随机试验。
在这项临床试验中,我们没有发现局限性和广泛性盆腔淋巴结清扫术在前列腺癌生化复发率方面存在差异。本研究在 ClinicalTrials.gov 上注册为 NCT01407263。